Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using their proprietary ProCellEx® plant cell-based protein expression system, has scheduled the release of its fiscal year 2024 financial results for March 17, 2025.
The company will host a conference call and webcast at 8:30 a.m. EDT on the same day, where management will discuss financial results and provide updates on corporate and regulatory developments. The call will feature a Call me™ functionality for easy access, and a replay will be available for two weeks on the company's website.
Protalix BioTherapeutics (NYSE American: PLX), una compagnia biofarmaceutica specializzata in proteine terapeutiche ricombinanti che utilizza il proprio sistema di espressione proteica a base di cellule vegetali ProCellEx®, ha programmato il rilascio dei suoi risultati finanziari per l'anno fiscale 2024 per il 17 marzo 2025.
La società ospiterà una conferenza telefonica e una trasmissione in diretta alle 8:30 EDT dello stesso giorno, durante la quale la direzione discuterà i risultati finanziari e fornirà aggiornamenti su sviluppi aziendali e normativi. La chiamata presenterà una funzionalità Call me™ per un accesso facile, e una registrazione sarà disponibile per due settimane sul sito web dell'azienda.
Protalix BioTherapeutics (NYSE American: PLX), una compañía biofarmacéutica especializada en proteínas terapéuticas recombinantes que utiliza su propio sistema de expresión proteica a base de células vegetales ProCellEx®, ha programado la publicación de sus resultados financieros del año fiscal 2024 para el 17 de marzo de 2025.
La compañía llevará a cabo una conferencia telefónica y una transmisión en vivo a las 8:30 a.m. EDT el mismo día, donde la dirección discutirá los resultados financieros y proporcionará actualizaciones sobre desarrollos corporativos y regulatorios. La llamada contará con una funcionalidad Call me™ para un acceso fácil, y una grabación estará disponible durante dos semanas en el sitio web de la compañía.
Protalix BioTherapeutics (NYSE American: PLX)는 독점적인 ProCellEx® 식물 세포 기반 단백질 발현 시스템을 사용하여 재조합 치료 단백질을 전문으로 하는 생물 제약 회사로, 2024 회계연도 재무 결과를 2025년 3월 17일에 발표할 예정입니다.
회사는 같은 날 오전 8시 30분 EDT에 컨퍼런스 콜 및 웹캐스트를 개최하며, 경영진이 재무 결과를 논의하고 기업 및 규제 개발에 대한 업데이트를 제공할 것입니다. 이 통화는 쉽게 접근할 수 있는 Call me™ 기능을 제공하며, 회사 웹사이트에서 2주 동안 다시 들을 수 있는 녹음이 제공될 것입니다.
Protalix BioTherapeutics (NYSE American: PLX), une entreprise biopharmaceutique spécialisée dans les protéines thérapeutiques recombinantes utilisant son propre système d'expression protéique à base de cellules végétales ProCellEx®, a prévu la publication de ses résultats financiers de l'exercice 2024 pour le 17 mars 2025.
L'entreprise tiendra une conférence téléphonique et un webinaire le même jour à 8h30 EDT, où la direction discutera des résultats financiers et fournira des mises à jour sur les développements d'entreprise et réglementaires. L'appel proposera une fonctionnalité Call me™ pour un accès facile, et un enregistrement sera disponible pendant deux semaines sur le site web de l'entreprise.
Protalix BioTherapeutics (NYSE American: PLX), ein biopharmazeutisches Unternehmen, das sich auf rekombinante Therapeutika spezialisiert hat und sein eigenes ProCellEx® pflanzenzellbasiertes Protein-Expressionssystem verwendet, hat die Veröffentlichung seiner Finanzergebnisse für das Geschäftsjahr 2024 für den 17. März 2025 angesetzt.
Das Unternehmen wird am selben Tag um 8:30 Uhr EDT eine Telefonkonferenz und einen Webcast abhalten, in dem das Management die Finanzergebnisse besprechen und Updates zu Unternehmens- und Regulierungsentwicklungen geben wird. Die Konferenz wird eine Call me™-Funktionalität für einen einfachen Zugang bieten, und eine Wiederholung wird zwei Wochen lang auf der Website des Unternehmens verfügbar sein.
- None.
- None.
Company to host conference call and webcast at 8:30 a.m. EDT
CARMIEL,
Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.
Conference Call Details:
Date: | Monday, March 17, 2025 |
Time: | 8:30 a.m. Eastern Daylight Time (EDT) |
Toll Free: | 1-877-423-9813 |
International: | 1-201-689-8573 |
Israeli Toll Free: | 1-809-406-247 |
Conference ID: | 13752080 |
Call me™: |
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
Webcast Details:
Company Link: | |
Webcast Link: | |
Conference ID: | 13752080 |
Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-fiscal-year-2024-financial-and-business-results-on-march-17-2025-302396854.html
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When will Protalix BioTherapeutics (PLX) release its fiscal year 2024 financial results?
What time is PLX's fiscal year 2024 earnings conference call scheduled?
How long will the replay of PLX's fiscal year 2024 earnings call be available?
What special feature does PLX offer for their earnings call access?
